Novel Biannual Antihypertensive Shows Potential for Combination Therapy

(MedPage Today) -- ATLANTA -- The novel RNA silencer zilebesiran reduced blood pressure (BP) when added to a diuretic, calcium channel blocker, or maximum-dose angiotensin receptor blocker, the phase II KARDIA-2 trial showed. At 3 months, the...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news